Details for Patent: 9,415,009
✉ Email this page to a colleague
Which drugs does patent 9,415,009 protect, and when does it expire?
Patent 9,415,009 protects AIRSUPRA, BEVESPI AEROSPHERE, BREZTRI AEROSPHERE, and SYMBICORT AEROSPHERE, and is included in four NDAs.
This patent has one hundred and ninety-two patent family members in thirty-two countries.
Summary for Patent: 9,415,009
| Title: | Compositions, methods and systems for respiratory delivery of two or more active agents |
| Abstract: | Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium. |
| Inventor(s): | Reinhard Vehring, Michael Steven Hartman, David Lechuga-Ballesteros, Adrian Edward Smith, Vidya B. Joshi, Sarvajna Kumar Dwivedi |
| Assignee: | Pearl Therapeutics Inc |
| Application Number: | US14/334,503 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,415,009 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
Drugs Protected by US Patent 9,415,009
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | AIRSUPRA | albuterol sulfate; budesonide | AEROSOL, METERED;INHALATION | 214070-001 | Jan 10, 2023 | RX | Yes | Yes | 9,415,009 | ⤷ Start Trial | AS-NEEDED TREATMENT OR PREVENTION OF BRONCHOCONSTRICTION AND REDUCTION OF THE RISK OF EXACERBATIONS IN PATIENTS WITH ASTHMA 18 YEARS OF AGE AND OLDER | ⤷ Start Trial | ||||
| Astrazeneca | BEVESPI AEROSPHERE | formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 208294-001 | Apr 25, 2016 | RX | Yes | Yes | 9,415,009 | ⤷ Start Trial | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | ⤷ Start Trial | ||||
| Astrazeneca Ab | BREZTRI AEROSPHERE | budesonide; formoterol fumarate; glycopyrrolate | AEROSOL, METERED;INHALATION | 212122-001 | Jul 23, 2020 | RX | Yes | Yes | 9,415,009 | ⤷ Start Trial | USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,415,009
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2435025 | ⤷ Start Trial | 300995 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2435025 | ⤷ Start Trial | PA2019014 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2435025 | ⤷ Start Trial | 122019000068 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
